Second, we cannot rule out the possibility that use of a wide range of antirheumatic drugs-including methotrexate, oral glucocorticoids, anti-TNF-α therapy and anti-IL-6 therapy that potently suppress specific inflammation, might be responsible for the differences in gene expression profiles in OA and RA patients’ MCs. This evidence concerns the gene TNF and rheumatoid arthritis.